HHS Finds ‘Questionable Billing’ for Compounded Topical Drugs in Medicare Part D

Drug Industry Daily
A A
The HHS Office of Inspector General flagged “questionable billing” and rapid growth in Medicare Part D spending for compounded topical drugs in a report released Thursday.

To View This Article:

Login

Subscribe To Drug Industry Daily